Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer

World Journal of Gastroenterology

Volumn 19, Issue 39, 2013, Pages 6630-6636

  Zhang, Qiang ^a   Li, Kun ^b   Xu, Jian Hua ^a   Zhao, Cheng Gen ^a   Gao, Qi ^c   Wu, Bin ^d   Liu, Xiao Yan ^d  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Linyi Center for Adverse Drug Reaction Monitoring   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ABCG2 mRNA expression; Cisplatin; Gastric cancer; Overall survival

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAPECITABINE; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROPYRIMIDINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MITOMYCIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; STOMACH CANCER;

ABCG2 MRNA EXPRESSION; CISPLATIN; GASTRIC CANCER; OVERALL SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CISPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA, MESSENGER; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84886900275     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i39.6630     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477-490 [PMID: 19625077 DOI: 10.1016/S0140-6736(09)60617-6]
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150 [PMID: 16682732 DOI: 10.1200/JCO.2005.05.2308]
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909 [PMID: 16782930 DOI: 10.1200/JCO.2005.05.0245]
5. Macdonald JS. Gastric cancer-new therapeutic options. N Engl J Med 2006; 355: 76-77 [PMID: 16822999 DOI: 10.1056/ NEJMe068121]
6. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007; 7: 1369-1378 [PMID: 17944563 DOI: 10.1586/14737140.7.10.1369]
7. Schnepf R, Zolk O. Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications. Expert Opin Drug Metab Toxicol 2013; 9: 287-306 [PMID: 23289909 DOI: 10.1517/17425255.20 13.742063]
8. Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012; 3: 1-27 [PMID: 22509477]
9. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 1691-1697 [PMID: 15014021]
10. Niu Q, Wang W, Li Y, Ruden DM, Wang F, Li Y, Wang F, Song J, Zheng K. Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation. PLoS One 2012; 7: e41035 [PMID: 22844424 DOI: 10.1371/journal.pone.0041035]
11. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-15670 [PMID: 9861027]
12. Diestra JE, Scheffer GL, Català I, Maliepaard M, Schellens JH, Scheper RJ, Germà-Lluch JR, Izquierdo MA. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198: 213-219 [PMID: 12237881]
13. Usuda J, Ohira T, Suga Y, Oikawa T, Ichinose S, Inoue T, Ohtani K, Maehara S, Imai K, Kubota M, Tsunoda Y, Tsutsui H, Furukawa K, Okunaka T, Sugimoto Y, Kato H. Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer. Lung Cancer 2007; 58: 296-299 [PMID: 17618705 DOI: 10.1016/ j.lungcan.2007.05.019]
14. Galimberti S, Nagy B, Benedetti E, Pacini S, Brizzi S, Caracciolo F, Papineschi F, Ciabatti E, Guerrini F, Fazzi R, Canestraro M, Petrini M. Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 2007; 48: 1502-1509 [PMID: 17701580 DOI: 10.1080/10428190701402895]
15. Font A, Taron M, Gago JL, Costa C, Sánchez JJ, Carrato C, Mora M, Celiz P, Perez L, Rodríguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L, Rosell R. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011; 22: 139-144 [PMID: 20603439 DOI: 10.1093/annonc/mdq333]
16. Damiani D, Tiribelli M, Michelutti A, Geromin A, Cavallin M, Fabbro D, Pianta A, Malagola M, Damante G, Russo D, Fanin R. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res 2010; 34: 942-945 [PMID: 20122734 DOI: 10.1016/ j.leukres.2010.01.008]
17. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004; 10: 7896-7902 [PMID: 15585622 DOI: 10.1158/1078-0432.CCR-04-0795]
18. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, Legrand O. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005; 11: 7764-7772 [PMID: 16278398 DOI: 10.1158/1078-0432. CCR-04-1895]
19. Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, Tanaka E, Watanabe G, Itami A, Sakai Y, Shimada Y. ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 2006; 71: 251-258 [PMID: 17671398]
20. Saglam A, Hayran M, Uner AH. Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. APMIS 2008; 116: 791-800 [PMID: 19024599]
21. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ, Vega F. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 2009; 22: 1312-1320 [PMID: 19593328 DOI: 10.1038/ modpathol.2009.98]
22. Furmaga WB, Tsongalis GJ, Wu AHB. Monitoring of subtherapeutic drug levels during cancer chemotherapy: a possible method to prevent acquired multidrug resistance. FASEB Journal 2003; 17: Abstract No. 384.387
23. Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012; 18: 1863-1869 [PMID: 22344233 DOI: 10.1158/1078-0432.ccr-11-1590]
24. Teng S, Piquette-Miller M. Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm 2008; 5: 67-76 [PMID: 18072749 DOI: 10.1021/mp700102q]
25. Malekshah OM, Lage H, Bahrami AR, Afshari JT, Behravan J. PXR and NF-κB correlate with the inducing effects of IL-1β and TNF-α on ABCG2 expression in breast cancer cell lines. Eur J Pharm Sci 2012; 47: 474-480 [PMID: 22750628 DOI: 10.1016/j.ejps.2012.06.011]
26. Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol 2008; 14: 7068-7074 [PMID: 19084913 DOI: 10.3748/wjg.14.7068]
27. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949-958 [PMID: 16054595 DOI: 10.1016/j.bcp.2005.06.018]
28. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem 2010; 285: 31100-31106 [PMID: 20705611 DOI: 10.1074/jbc.M110.155309]
29. Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, Harper PA, Ito S. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. Mol Pharmacol 2013; 83: 377-388 [PMID: 23150485 DOI: 10.1124/mol.112.082362]